1 Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D: A: D Study. Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-577. abstract

2 Development and validation of a risk-score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. A Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT, SMART and ESPRIT study group. PlOS Medicine 2015 Mar 31; 12 (3). abstract